Juan-José Garcés
Has grant
Research Scholar
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Utilizing cell-free DNA for the selection of new immune-based therapies in multiple myeloma patients
Open Date: 2026-01-01
Close Date: 2027-01-01
Articles (10)
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction.
Year:
2025
Circulating tumor cells (CTCs) have emerged as a key prognostic factor in newly diagnosed multiple myeloma (NDMM). However, it remains unclear if high CTC counts represent a mere surrogate of tumor burden or might reflect a distinct genomic or transcriptomic entity. In this study, we characterized the genomic and transcriptomic features associated with CTC burden and assessed their combined prognostic value in NDMM patients. We analyzed 540 NDMM patients from the CoMMpass dataset with available baseline CTC information and matched bone marrow transcriptomic ( n = 374) and genomic ( n = 460) sequencing data. We then validated the results on an external cohort of 135 NDMM patients with CTCs enumerated by next‐generation flow cytometry. Higher CTC levels were significantly associated with high‐risk clinical features (e.g., ISS or IMS/IMWG 2024). Furthermore, genomic analyses revealed that high CTC counts were associated with complex genomic features such as chromothripsis, APOBEC mutagenesis, and loss of key tumor suppressors, typically linked to high‐risk disease. Transcriptomic analyses revealed that elevated CTCs were enriched in cell cycle and proliferation (PR) genes while presenting a reduced association with immune response. Importantly, CTCs also emerged as a surrogate for PR transcriptomic signatures and demonstrated prognostic superiority, potentially simplifying application in the clinical setting. Elevated CTC levels reflect aggressive biological features of multiple myeloma and outperform prognostic markers such as PR signatures. Integrating CTC data into genomic and transcriptomic classifiers could enhance risk stratification and provide a streamlined and powerful tool for clinical decision‐making in NDMM.
Year:
2025
Purpose: Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transplantation. Baseline and longitudinal measurable residual disease (MRD) negative status is a well-established positive predictive sign in Len maintenance patients. However, the clinical utility of serial MRD assessments remains uncertain, as there is no consensus on the clinical management of MRD resurgence (MRDres) or stable remissions in patients positive for MRD. Patients and Methods: In this study, we report the complete and final results of a phase II, single-arm study of 5 years of continuous Len maintenance in patients with multiple myeloma following unrestricted upfront therapy, along with exploratory peripheral blood T cell profiling experiments performed via high-dimensional spectral cytometry. Results: Patients with MRDres had inferior progression-free survival compared with those with sustained MRD negativity at the 1- and 2-year landmarks (P = 0.036, P = 0.0014, respectively); however, myeloma progression only occurred within 2 years of MRDres in 36% of patients, with no progression observed in the remaining 64% of patients at the last follow-up. Exploratory peripheral blood T cell profiling experiments throughout the trial period identified an immune signature of early relapse in patient cohorts both negative and positive for MRD at the start of maintenance therapy. T cell profiles enriched with activated cytotoxic effectors predicted early relapse, whereas quiescent T cell profiles enriched with naïve T cell populations predicted durable remissions. Conclusions: This “immune MRD” status showed predictive potential and segregated patients with MRDres and early disease progression from patients with sustained remission despite MRDres.
Year:
2025
Purpose: Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transplantation. Baseline and longitudinal measurable residual disease (MRD) negative status is a well-established positive predictive sign in Len maintenance patients. However, the clinical utility of serial MRD assessments remains uncertain, as there is no consensus on the clinical management of MRD resurgence (MRD res ) or stable remissions in patients positive for MRD. Patients and Methods: In this study, we report the complete and final results of a phase II, single-arm study of 5 years of continuous Len maintenance in patients with multiple myeloma following unrestricted upfront therapy, along with exploratory peripheral blood T cell profiling experiments performed via high-dimensional spectral cytometry. Results: Patients with MRD res had inferior progression-free survival compared with those with sustained MRD negativity at the 1- and 2-year landmarks ( P = 0.036, P = 0.0014, respectively); however, myeloma progression only occurred within 2 years of MRD res in 36% of patients, with no progression observed in the remaining 64% of patients at the last follow-up. Exploratory peripheral blood T cell profiling experiments throughout the trial period identified an immune signature of early relapse in patient cohorts both negative and positive for MRD at the start of maintenance therapy. T cell profiles enriched with activated cytotoxic effectors predicted early relapse, whereas quiescent T cell profiles enriched with naïve T cell populations predicted durable remissions. Conclusions: This “immune MRD” status showed predictive potential and segregated patients with MRD res and early disease progression from patients with sustained remission despite MRD res .
Year:
2025
Year:
2023
Year:
2023
Collaborators (23)
Esteban Braggio
Assistant Professor
Mayo Clinic
Andriy Derkach
Associate Attending Biostatistician
Memorial Sloan Kettering Cancer Center
ROSA MARIA AYALA DIAZ
Full Professor
Universidad Complutense de Madrid
Ola Landgren
Professor of Medicine
Sylvester Comprehensive Cancer Center, University of Miami
Sergio Giralt
Chief Attending, Adult BMT Service
Memorial Sloan Kettering Cancer Center
Giancarlo Castellano
Fondazione IRCCS Istituto Nazionale dei Tumori
Urvi Shah
Assistant Attending, Myeloma Service
Memorial Sloan Kettering Cancer Center
Roman Hajek
University of Ostrava
Gunjan Shah
Memorial Sloan Kettering Cancer Center
Ana Alfonso-Piérola
MD, PhD
Clinica Universidad de Navarra
Joseph Deasy
Professor of Medical Physics
Weill Cornell Medicine
Jonathan Peled
Director
Memorial Sloan Kettering Cancer Center
Mario Nuvolone
University of Pavia
Niccolò Bolli
Associate Professor
University of Milan
Saad Usmani
Chief Attending
Memorial Sloan Kettering Cancer Center
Sridevi Rajeeve
Memorial Sloan Kettering Cancer Center
Mattia D'Agostino
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
Anita D'Souza
Medical College of Wisconsin
Ramón García-Sanz
Profesor Titular de Medicina / Hematología
Universidad Complutense de Madrid
Hamza Hashmi
Memorial Sloan Kettering Cancer Center
Francesco Maura
Assistant Professor
Sylvester Comprehensive Cancer Center
Bruno David Lourenço Paiva
Clinica Universidad de Navarra
Patrick Blaney
Senior Bioinformatics Programmer
NYU Langone Health
Make your next move.
Prepare your application
Review drafts before you send them.